(Q33375262)

26 July 2017

title

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma (English)

1 reference

26 July 2017

1 reference

1 reference

Raffaella Marcheselli

object named as

Raffaella Marcheselli

3

0 references

Francesco Merli

object named as

Francesco Merli

7

0 references

Stefano Sacchi

object named as

Stefano Sacchi

1

0 references

author name string

Samantha Pozzi

2

1 reference

26 July 2017

Massimo Federico

4

1 reference

26 July 2017

Massimo Federico

5

1 reference

26 July 2017

Alessandra Tucci

6

1 reference

26 July 2017

Loretta Orsucci

8

1 reference

26 July 2017

Marina Liberati

9

1 reference

26 July 2017

Daniele Vallisa

10

1 reference

26 July 2017

Maura Brugiatelli

11

1 reference

26 July 2017

Italian Lymphoma Study Group

12

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

26 July 2017

number of pages

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

26 July 2017

volume

110

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

121-128

1 reference

Current controversies in follicular lymphoma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

t(14;18), a journey to eternity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Follicular lymphoma: prognostic factors for response and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Meta-analysis to evaluate the role of interferon in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

New treatment options have changed the survival of patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Controversies in the adjuvant treatment of breast cancer: the role of taxanes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Severe immunodeficiency in patients treated with fludarabine monophosphate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22740

7 January 2021

Identifiers

DOI

10.1002/CNCR.22740

1 reference

26 July 2017

1 reference